LEXINGTON, Ky. and KALAMAZOO, Mich., Nov. 29 /PRNewswire/ -- NanoMed
Pharmaceuticals, Inc. founders Michael Jay, Ph.D. and Russell J. Mumper, Ph.D.
have been issued U.S. Patent 6,855,270 entitled "NanoScintillation Systems For
Aqueous-Based Liquid Scintillation Counting." Their invention, assigned to the
University of Kentucky Research Foundation and licensed exclusively to NanoMed
Pharmaceuticals, covers processes to make nanoparticle-based NanoScintillation
Systems which are used to detect beta-particle- or alpha-particle-emitting
radioisotopes without the use of the organic solvents commonly used in
conventional liquid scintillation (LS) "cocktails."
Biomedical and environmental researchers routinely employ scintillation
cocktails to quantify, or "count," the amount of radioactivity emitted by
radioisotopes in samples generated during laboratory experiments. Frequently,
these samples must be mixed with an organic solvent containing dissolved fluor
molecules, or "scintillators." Although efficient, the use of organic-based LS
cocktails results in the need to dispose of large quantities of mixed low-
level radioactive and hazardous waste ("Mixed LLW") generated as a byproduct
of the counting process. Results of testing by TestAmerica, Inc.,
(http://www.testamericainc.com/ ), the leading nationally certified provider
of outsourced analytical laboratory, air emissions, and indoor air quality
testing services, show that the NanoScintillation System was qualified as non-
hazardous waste by virtue of passing tests for Toxicity Characteristic
Leaching Procedure (TCLP) Extraction by EPA 1311, TCLP for Volatile Organic
Compounds by EPA Method 1311/8260B, TCLP for Semi-volatile Organic Compounds
by EPA Method 1311/8270C, TCLP for Metals by 6000/7000 Series Methods,
Reactivity, pH, and Ignitability as specified in Subpart C of 40 CFR Part 261.
Thus, the NanoScintillation System represents an opportunity to significantly
reduce hazardous environmental waste.
"With the advent of nanotechnology, methods now exist to enhance the
aqueous solubility of fluor molecules without the use of organic solvents,"
said Michael Jay, Ph.D., NanoMed co-founder and Director of the University of
Kentucky's Center for Pharmaceutical Science & Technology. "The development of
NanoScintillation Systems provides the potential for tremendous scientific,
economic, and environmental advantages, most notably the opportunity to
greatly reduce the amount of mixed radioactive and hazardous waste generated
through the widespread use of conventional organic-based LS cocktails," Dr.
Background and Significance
According to a 1990 baseline report commissioned by the Nuclear Regulatory
Commission and the Environment Protection Agency titled "National Profile on
Commercially Generated Low-Level Radioactive Mixed Waste" (NUREG/CR-5938),
140,000 cubic feet of mixed waste was generated by industry and academia in
the United States in 1990 alone. It is estimated that the Department of Energy
generates annually an additional 800,000 cubic feet of mixed organic and
Additional Potential Applications
In addition to its application in routine scintillation counting in
biomedical and pharmaceutical research laboratories, NanoScintillation Systems
may have utility in homeland security applications; specifically, anti-nuclear
terrorism of municipal and military water supplies. Several U.S. government
agencies have made nuclear preparedness recommendations that included the use
of mobile methods to detect radiation, including beta-particle- or alpha-
NanoScintillation Systems may also have applications in other areas such
as in radioisotopic binding assays and in functional genomics whereby the
binding of radiolabeled probes in DNA microarrays can be quantified which may
be of particular interest to biomedical researchers who build their own gene
chips and need high sensitivity detection.
About the Inventors
Michael Jay, Ph.D. is Professor in the University of Kentucky Department
of Pharmaceutical Sciences with a joint appointment in the Department of
Diagnostic Radiology of the Chandler Medical Center, and Director of the
University of Kentucky's Center for Pharmaceutical Science and Technology.
Russell J. Mumper, Ph.D. is Vice Chair and Associate Professor in the
University of Kentucky, College of Pharmacy, Department of Pharmaceutical
Sciences, and Associate Director of the University of Kentucky's Center for
Pharmaceutical Science & Technology
About NanoMed Pharmaceuticals, Inc.
NanoMed Pharmaceuticals, Inc. is an advanced drug delivery systems company
developing therapeutic and diagnostic products to treat or detect disease.
The Company's initial focus is cancer therapeutics and diagnostics. NanoMed's
core technology is Nanotemplate Engineering(TM), a flexible, rapid and
scaleable nanoparticle manufacturing technology for the delivery of small
molecules, peptides, proteins, plasmid DNA, and diagnostic agents.
SOURCE NanoMed Pharmaceuticals, Inc.